A detailed history of Nadler Financial Group, Inc. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Nadler Financial Group, Inc. holds 7,964 shares of HRMY stock, worth $271,014. This represents 0.03% of its overall portfolio holdings.

Number of Shares
7,964
Previous 9,361 14.92%
Holding current value
$271,014
Previous $257,000 5.45%
% of portfolio
0.03%
Previous 0.02%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 28, 2026

SELL
$25.9 - $34.29 $36,182 - $47,903
-1,397 Reduced 14.92%
7,964 $271,000
Q3 2025

Oct 30, 2025

BUY
$26.76 - $38.05 $250,500 - $356,186
9,361 New
9,361 $257,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.01B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Nadler Financial Group, Inc. Portfolio

Follow Nadler Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nadler Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Nadler Financial Group, Inc. with notifications on news.